BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 12601150)

  • 1. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
    Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein.
    Lauwers E; Debyser Z; Van Dorpe J; De Strooper B; Nuttin B; Baekelandt V
    Brain Pathol; 2003 Jul; 13(3):364-72. PubMed ID: 12946025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease.
    McFarland NR; Fan Z; Xu K; Schwarzschild MA; Feany MB; Hyman BT; McLean PJ
    J Neuropathol Exp Neurol; 2009 May; 68(5):515-24. PubMed ID: 19525899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
    Dong Z; Ferger B; Feldon J; Büeler H
    J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
    Henrich MT; Geibl FF; Lee B; Chiu WH; Koprich JB; Brotchie JM; Timmermann L; Decher N; Matschke LA; Oertel WH
    Acta Neuropathol Commun; 2018 May; 6(1):39. PubMed ID: 29747690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.
    Sherer TB; Kim JH; Betarbet R; Greenamyre JT
    Exp Neurol; 2003 Jan; 179(1):9-16. PubMed ID: 12504863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
    Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease.
    Olsen LK; Cairns AG; Ådén J; Moriarty N; Cabre S; Alamilla VR; Almqvist F; Dowd E; McKernan DP
    Brain Behav Immun; 2019 Aug; 80():525-535. PubMed ID: 31029796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.
    Chu Y; Muller S; Tavares A; Barret O; Alagille D; Seibyl J; Tamagnan G; Marek K; Luk KC; Trojanowski JQ; Lee VMY; Kordower JH
    Brain; 2019 Nov; 142(11):3565-3579. PubMed ID: 31580415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.